^
    Back
    Association details:
    Biomarker:MYC positive
    Cancer:Non-Hodgkin’s Lymphoma
    Regimen:EPOCH (cyclophosphamide + doxorubicin hydrochloride + etoposide IV + methylprednisolone oral + vincristine)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Blood
    Title:

    Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial)

    Published date:
    09/10/2020
    Excerpt:
    ...patients with Myc+ DLBCL had a significantly lower EFS. A low diagnosis-to treatment interval (DTI) was also associated with inferior outcomes, whereas preprotocol therapy had no negative impact. In summary, EPOCH had broad efficacy against highly aggressive HIV NHLs, whereas vorinostat had no benefit; patients with Myc-driven DLBCL, low CD4, and low DTI had less favorable outcomes. 
    DOI:
    10.1182/blood.2019003959